Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
The study was double-blind and placebo-controlled. Patients had HCV GT1, GT4, or GT6 and were on opioid therapy. Upwards of 96% of the patients achieved SVR24. This study contributed to the knowledge of the incidence of HCV reinfection in patients who receive drug injection of opioid treatments. This is a demographic that the medical community is typically reluctant to treat due to concerns of reinfection and compliance.
== Early life and education == Scrutton was born in Batley, West Riding of Yorkshire and was brought up in Cleckheaton where he went to Whitcliffe Mount School. Scrutton graduated from King's College London with a first class Bachelor of Science degree in Biochemistry in 1985. He was a Benefactors' Scholar at St John's College, Cambridge where he completed his doctoral research (PhD) in 1988 supervised by Richard Perham. He was a Research Fellow of St John's College, Cambridge (1989–92) and a Fellow / Director of Studies at Churchill College, Cambridge (1992–95). He was awarded a Doctor of Science (ScD) degree in 2003 by the University of Cambridge.
Reticular formation, a region in the brainstem that is involved in multiple tasks Reticular activating system, a set of connected nuclei in the brains of vertebrates Reticular cell, a type of fibroblast that produces reticular fibers Reticular connective tissue, a type of connective tissue that has a network of reticular fibers Reticular fiber, a type of fiber in connective tissue that is composed of type III collagen Reticular dermis, the lower layer of the dermis composed of dense irregular connective tissue Reticular dysgenesis, a rare genetic disorder of the bone marrow Reticular erythematous mucinosis, a skin condition that tends to affect women in the third and fourth decades of life Reticular layer, a layer in the adrenal cortex that produces androgens Reticular pigmented anomaly of the flexures, a fibrous anomaly of the flexures or bending parts of the axillae, neck and inframammary/sternal areas
Sources: en.wikipedia.org
The authors suggested that PDE3 inhibitors might be repurposed for short-stature disorders such as achondroplasia, while cautioning that the findings are preclinical and that self-administration of cilostazol for growth purposes is unsupported and carries cardiovascular and bleeding risks.
Bombesin-like peptides comprise a large family of peptides which were initially isolated from amphibian skin, where they stimulate smooth muscle contraction. They were later found to be widely distributed in mammalian neural and endocrine cells. The amphibian peptides which belong to this family are currently classified into three subfamilies; the Bombesin group, which includes bombesin and alytesin; the Ranatensin group, which includes ranatensins, litorin, and Rohdei litorin; and the Phyllolitorin group, which includes Leu(8)- and Phe(8)-phyllolitorins. In mammals and birds two categories of bombesin-like peptides are known, gastrin-releasing peptide (GRP), which stimulates the release of gastrin as well as other gastrointestinal hormones, and neuromedin B (NMB), a neuropeptide whose function is not yet clear. Bombesin-like peptides, like many other active peptides, are synthesized as larger protein precursors that are enzymatically converted to their mature forms. The final peptides are eight to fourteen residues long.
== Therapeutic uses == Inhibition of the norepinephrine transporter (NET) has potential therapeutic applications in the treatment of attention deficit hyperactivity disorder (ADHD), substance abuse, neurodegenerative disorders (e.g., Alzheimer's disease (AD) and Parkinson's disease (PD)) and clinical depression.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.